Clinical Trial Update: Phase III Clinical Study of MG-K10 Humanized Mab Injection in Subjects With Prurigo Nodularis [Phase 3]

View source ↗

Summary

Phase 3 clinical trial of MG-K10, a humanized monoclonal antibody injection, for prurigo nodularis is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prurigo Nodularis

Drugs mentioned

• MG-K10

Snippet

Sponsor: Shanghai Mabgeek Biotech.Co.Ltd | Conditions: Prurigo Nodularis | Phase 3 | Status: RECRUITING